Fig. 1: Timelines of treatments, tumour biopsies and blood sample collection for cfDNA and CTC analysis.

CtDNA monitoring data is also provided. Only cfDNA mutations with a VAF threshold ≥ 0.25% are presented, except for BRAF^V600E mutation from patient P4 (VAF, 0.06875%).